November 18, 2026
Health news, explained with evidence
LIVE

Single CRISPR Infusion Successfully Lowers Blood Fats in Three-Year Primate Study

🥗 Nutrition 2 min read 👁 4

A new preclinical study published in Nature shows that a single gene-editing infusion can durably reduce triglycerides and cholesterol in monkeys for up to three years.

Single CRISPR Infusion Successfully Lowers Blood Fats in Three-Year Primate Study🥗Nutrition

Photo: Medical Xpress

Key points

  • A single CRISPR infusion lowered triglycerides and cholesterol in monkeys for three years.
  • The therapy targets the ANGPTL3 gene to prevent the liver from producing a lipid-clearing inhibitor.
  • Human clinical trials are currently underway to test the safety and efficacy of the human version, VERVE-201.

Elevated levels of low-density lipoprotein cholesterol and triglycerides are significant risk factors for atherosclerotic cardiovascular disease. While traditional management relies on ongoing medications, investigators from Verve Therapeutics and partner institutions explored a more permanent solution using gene-editing technology. Their recent findings, published in the journal Nature, demonstrate that a single administration of a CRISPR treatment can sustainably lower lipid levels in animal models.

The intervention is designed to target the ANGPTL3 gene, which produces a hepatic protein responsible for slowing down the clearance of fats from the bloodstream. By utilizing tiny fat-based particles outfitted with a sugar-based targeting molecule known as GalNAc, the researchers delivered RNA instructions directly to the liver cells. This mechanism alters a single DNA letter to disable the ANGPTL3 gene, effectively stopping the liver from manufacturing the targeted protein.

In a three-year durability trial involving primates with normal blood lipids, the treatment reduced circulating ANGPTL3 protein levels by an average of 94 percent compared to baseline. Triglycerides fell by 43 percent, while LDL cholesterol decreased by a more modest 13 percent. Additional testing on animals with a severe shortage of LDL receptors showed a substantial 46 percent drop in LDL cholesterol over 35 days. Liver enzymes experienced a temporary rise but normalized within two weeks, and tissue evaluations revealed no signs of long-term hepatic toxicity.

What to know: The human-adapted version of this therapeutic approach, known as VERVE-201, is currently undergoing early-stage phase 1b clinical evaluation in patients with poorly controlled blood lipids. Because these findings stem from animal experiments and early trials, researchers emphasize that long-term safety and efficacy in humans remain to be established. Readers should consult a qualified healthcare provider for personalized guidance regarding cardiovascular health and lipid management.

Source Medical Xpress — medicalxpress.com/news/2026-11-crispr-infusion-lowers-blood-fats.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.